Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Debt: 2016-2025

Historic Total Debt for Myriad Genetics (MYGN) over the last 7 years, with Sep 2025 value amounting to $119.5 million.

  • Myriad Genetics' Total Debt rose 206.41% to $119.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.5 million, marking a year-over-year increase of 206.41%. This contributed to the annual value of $39.6 million for FY2024, which is 2.86% up from last year.
  • Latest data reveals that Myriad Genetics reported Total Debt of $119.5 million as of Q3 2025, which was up 101.18% from $59.4 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Total Debt ranged from a high of $119.5 million in Q3 2025 and a low of $38.4 million during Q2 2023.
  • Over the past 3 years, Myriad Genetics' median Total Debt value was $38.9 million (recorded in 2024), while the average stood at $51.0 million.
  • Data for Myriad Genetics' Total Debt shows a peak YoY soared of 3,258.06% (in 2021) over the last 5 years.
  • Quarterly analysis of 4 years shows Myriad Genetics' Total Debt stood at $104.1 million in 2021, then reached $38.5 million in 2023, then increased by 2.86% to $39.6 million in 2024, then skyrocketed by 206.41% to $119.5 million in 2025.
  • Its Total Debt stands at $119.5 million for Q3 2025, versus $59.4 million for Q2 2025 and $59.3 million for Q1 2025.